Alloimmune refractoriness to platelet transfusions

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 470-473

  Sandler, S Gerald ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD SUBSTITUTE; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; FREEZE DRYING; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOGENICITY; LEUKAPHERESIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SHORT SURVEY; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET B RADIATION;

EID: 0030784628     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00020     Document Type: Short Survey

References (35)

1. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD: Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993, 81:3428-3434.
2. Rodey GE: Class I antigens: HLA-A, -B, -C and cross-reactive groups. In Scientific and Technical Aspects of the Major Histocompatibility Complex. Edited by Moulds JM, Fawcett KJ, Garner RJ. Arlington, VA: American Association of Blood Banks; 1989:23-40.
3. O'Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA: Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 1992, 79:527-531.
4. Friedberg RC, Donnelly SF, Mintz PD: Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994, 34:215-220.
5. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, et al.: Selection of platelets for refractory patients by HLA matching and prospective cross matching. Transfusion 1992, 32:633-640.
6. Gelb AB, Leavitt AD: Crossmatch-compatible platelets improve • corrected count increments In patients who are refractory to randomly selected platelets. Transfusion 1997, 37:624-630. A total of 475 crossmatch-compatible platelet transfusions were administered to 66 patients who were refractory to random donor platelets. In 59% of patients, the mean corrected platelet count increment increased by at least 7500.
7. A2) and multiple HLA antibodies. Transfusion 1988, 28:597-600.
8. von dem Borne AEG Kr, Verheugt FWA, Oosterhof F, von Riesz, E, Brutel de la Rivière A, Engelfriet CP: A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978, 39:195-207.
9. a involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989, 56:283-287.
10. Uhrynowska M, Zupanska: Platelet-specific antibodies in transfused • patients. Eur J Haematol 1996, 56:248-251. Using three sensitive laboratory methods, the authors detected platelet-reactive antibodies in 30.8% of transfused patients with hematologic diseases. This rate of alloimmunization compares with 20% to 70% reported by others.
11. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM: Intravenous anti-D treatment of Immune thrombocytopenic purpura: analysis of efficacy, toxicity and mechanism of effect Blood 1991, 77:1884-1893.
12. Fehr J, Hoffman V, Kappeler U: Transient reversal of thrombocytopenla in idiopathic thrombocytopenic purpura by high dose intravenous gammaglobulin. N Engl J Med 1982, 306:1254-1258.
13. Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D: High-dose Intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984, 64:937-940.
14. Kekomäki R, Elfenbein G, Gardner R, Graham-Pole J, Mehta P, Gross S: Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin. Am J Med 1984, 76:199-203.
15. Junghans RP, Ahn YS: High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets. Am J Med 1984, 76:204-208.
16. Kickler T, Braine HG, Piantadosi S, Ness PM, Herman JH, Rothko K: A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990, 74:313-316.
17. Zeigler ZR, Shadduck RK, Rosenfeld CS, Mangan KF, Winkelstein A, Oral A, Ramsey GE, Duquesnoy RJ: High-dose intravenous gamma globulin improves responses to single-donor platelets In patients refractory to platelet transfusion. Blood 1987, 70:1433-1436.
18. Zeigler AR, Shadduck RK, Rosenfeld CS, Winkelstein A, Przepiorka D, Kiss JE, Duquesnoy RJ, Marrari M: Intravenous gamma globulin decreases platelet associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991, 38:15-23.
19. Chen S, Liang D, Lin M: Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia. Am J Hematol 1995, 49:165-166.
20. Heddle NM, Klama L, Kelton JG, Meyer R, Walter I, Dickson L, Chambers S, Levine M: The use of anti-D to improve post-transfusion platelet response: a randomized trial. Br J Haematol 1995, 89:163-168.
21. Sugawara S, Abo T, Kumagai K: A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 1987, 100:83-90.
22. Kurata Y, Oshida M, Take H, Furubayashi T, Nakao H, Tomiyama Y, Kanayama Y, Nagao N, Okubo Y, Yonezawa T, Tarui S: New approach to eliminate HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0. Vox Sang 1989, 57:199-204.
23. Shanwell A, Sallander S, Olsson I, Gullikson H, Pedajas I, Lerner R: An alloimmunized, thrombocytopenic patient successfully transfused with acid treated, random-donor platelets. Br J Haematol 1991, 79:462-465.
24. Novotny VMJ, Huizinga TWJ, van Doom R, Briët E, Brand A: HLA class I• eluted platelets as an alternative to HLA-matched platelets. Transfusion 1996, 36:438-444. Using citric acid, the authors decreased HLA expression on human platelets while preserving platelet-specific glycoproteins. Three of four patients transfused with HLA-eluted platelets had satisfactory outcomes. A fourth patient developed chills after the transfusion.
25. Sirchia G: HLA reduced platelets to overcome platelet refractoriness: • can lemons help [editorial]? Transfusion 1996, 36:388-391. This editorial includes a report of 52 crossmatch-compatible platelet transfusions in 19 refractory patients, with satisfactory post-transfusion corrected platelet count increments in 65%. A trial of acid-treated platelets resulted in 20% to 30% platelet loss. Tests to predict viability showed decreased but acceptable results.
26. Chao FC, Kim BK, Houranieh AM, Liang FH, Konrad MW, Swisher SN, Tullis JL: Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Transfusion 1996, 36:536-542. Infusible platelet membranes were administered (2 mg/kg) to thrombocytopenic rabbits, with decrease in bleeding times. The method for preparing IPMs is described.
27. Scigliano E, Fruchtman S, Isola L, Murphy W, Telen M, Smith D, Houranieh A, Shoemaker D, Sidor C: Infusible platelet membrane (IPM™) for control of bleeding in thrombocytopenic patients [abstract]. Blood 1995, 86:446a.
28. Coller BS, Springer KT, Beer JH, Mohandas N, Scudder LE, Norton KJ, West SM: Thromboerythrocytes: in vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89:546-555.
29. Yen RCK, Ho TWC, Blajchman MA: A novel approach to correcting the bleeding associated with thrombocytopenia [abstract #5161]. Transfusion 1995, 35:41S.
30. Blajchman MA, Lee DH: The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997, 11:95-105.
31. Read M, Reddick RL, Bode AP, Bellinger DA, Nichols TC, Taylor K, Smith SV, McMahon DK, Griggs TR, Brinkhous KM: Rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci U S A 1995, 92:397-401.
32. Novotny VMJ, Doom RV, Vitvliet D, Claas MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of pre-storage filtered platelets and red blood cells: a prospective study. Blood 1995, 85:1736-1741.
33. Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, Norfolk DR, for the Alloimmunisation Study Group: Bedside filtration of blood products in the prevention of HLA alloimmunization: a prospective randomized study. Blood 1994, 83:3028-3035.
34. Blundell EL, Pamphilon DH, Fraser ID, Menitove JE, Greenwalt TJ, Snyder • EL, Reppucci AJ, Hedberg SL, Anderson JK, Buchholz DH, Kagen LR, Aster RH: A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996, 36:296-302. Ultraviolet B irradiation did not diminish the clinical efficacy of platelet transfusions. The reduction in alloimmunized recipients was not statistically significant.
35. Pamphilon DH, Blundell EL: Ultraviolet-B irradiation of platelet concentrates: a strategy to reduce transfusion recipient allosensitization. Semin Hematol 1992, 29:113-121.